Irbesartan improves arterial compliance more than lisinopril

Figures & data

Table 1 Characteristics of the study population at baseline

	Mean ± SD	Range
Age (years)	65.1 ± 9.5	53–80
Systolic blood pressure (mmHg)	162.4 ± 12.9	135–178
Diastolic blood pressure (mmHg)	98.7 ± 8.1	82–110
PWV carotid-femoral (m/s)	15.1 ± 5.0	9.3–29.3
PWV carotid-radial (m/s)	12.4 ± 2.3	9.4–16.8
PWV femoral-dorsalis pedis (m/s)	11.0 ± 2.6	7.3–17.2
Triglycerides (mmol/L)	1.9 ± 0.98	1.0–5.0
Cholesterol (mmol/L)	6.2 ± 1.47	3.6–9.2
LDL cholesterol (mmol/L)	4.1 ± 1.44	1.2–6.6
HDL cholesterol (mmol/L)	1.28 ± 0.68	0.5–3.5
Height (cm)	166.3 ± 9.4	152–181
Weight (kg)	77.8 ± 15.7	47–96
BMI (kg/m^2)	28.4 ± 5.2	20.4–38.4

Abbreviations: BMI, body mass index; PWV, pulse wave velocity; LDL cholesterol, low-density lipoprotein cholesterol; HDL, high-density lipoprotein cholesterol.

Figure 1 Blood pressure systolic (SBP) and diastolic (DBP) at baseline and after 12 weeks treatment with irbesartan and lisinopril. The changes are statistically significant for both drugs (p < 0.05) for SBP and DBP.

Table 2 Baseline and end of trial results

	Baseline	12 weeks irbesartan	12 weeks lisinopril	p value irbesartan vs lisinopril
SBP (mmHg)	162.4 ± 12.9	134.5 ± 14.8*	145.2 ± 25*	0.08
DBP (mmHg)	98.7 ± 8.1	78.6 ± 9.2*	84.1 ± 11.6*	0.08
PWV (CF) (m/sec)	15.1 ± 5	13.3 ± 2.6**	14 ± 4.7*	0.345
PWV (CF) (m/sec) adjusted for SBP = 150 mmHg	14.9 ± 4	13.6 ± 3.2**	15.6 ± 4.9*	0.241
PWV (CR) (m/sec)	12.4 ± 2.3	11.6 ± 2.2	12.4 ± 2.4	0.126
PWV (CR) (m/sec) adjusted for SBP = 150 mmHg	12.2 ± 1.9	11.8 ± 2.4*	12.6 ± 2.5	0.042
PWV (FD) (m/sec)	11 ± 2.6	10.1 ± 2.4*	11.4 ±1.5	0.01
PWV (FD) (m/sec) adjusted for SBP = 150 mmHg	10.7 ± 1.4	10.9 ± 2.3**	11.7 ± 2.4	<0.001

* p < 0.05,

** p < 0.01 – Baseline vs 12 weeks treatment

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure; PWV (CF), pulse wave velocity carotid-femoral; PWV (CR), pulse wave velocity carotid-radial; PWV (FD), pulse wave velocity femoral-dorsalis.